Key result
Post-diagnostic low-dose aspirin use was not associated with a reduction in colorectal cancer-specific mortality compared to non-users (HR 1.17).
Why the study?
Does low-dose aspirin use after diagnosis reduce colorectal cancer-specific mortality in patients with Dukes' A-C colorectal cancer?
Cohort (n=8,391)
Does low-dose aspirin use after diagnosis reduce colorectal cancer-specific mortality in patients with Dukes' A-C colorectal cancer?
Hazard Ratio: 1.17 (95% CI 1–1.36)
p-value: p=0.06
Low-dose aspirin use after diagnosis does not prolong survival in patients with colorectal cancer.
No survival benefit with post-diagnostic aspirin in Dukes' A-C CRC; leaves open randomized confirmation before any practice change.
BACKGROUND: Aspirin has been proposed as a novel adjuvant agent in colorectal cancer (CRC). Six observational studies have reported CRC-specific survival outcomes in patients using aspirin after CRC diagnosis but the results from these studies have been conflicting. Using a population-based cohort design this study aimed to assess if low-dose aspirin use after diagnosis reduced CRC-specific mortality. METHODS: A cohort of 8391 patients with Dukes' A-C CRC (2009-2012) was identified from the Scottish Cancer Registry and linked to national prescribing and death records. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for CRC-specific mortality were calculated using time-dependent Cox regression. RESULTS: There were 1064 CRC-specific deaths after a median follow-up of 3.6 years. Post-diagnostic low-dose aspirin use was not associated with a reduction in CRC-specific mortality either before or after adjustment for confounders (adjusted HR = 1.17, 95% CI 1.00-1.36). In sensitivity analysis pre-diagnostic low-dose aspirin was also not associated with reduced CRC-specific mortality (adjusted HR = 0.96, 95% CI 0.88-1.05). CONCLUSION: Low-dose aspirin use, either before or after diagnosis, did not prolong survival in this population-based CRC cohort.
No takes yet. Share an insight, caveat, or question.
Gray et al. (2018) conducted a cohort in Colorectal cancer (n=8,391). Low-dose aspirin vs. Non-users was evaluated on Colorectal cancer-specific mortality (HR 1.17, 95% CI 1.00-1.36, p=0.06). Post-diagnostic low-dose aspirin use was not associated with a reduction in colorectal cancer-specific mortality compared to non-users (HR 1.17).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: